<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948194</url>
  </required_header>
  <id_info>
    <org_study_id>09-0137</org_study_id>
    <nct_id>NCT00948194</nct_id>
  </id_info>
  <brief_title>Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation</brief_title>
  <official_title>Investigation of the Effect of Nitric Oxide on Ischemic Reperfusion Injury During Extended Donor Criteria Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the researchers propose to investigate the efficacy of inhaled nitric oxide to&#xD;
      prevent ischemia-reperfusion (I/R) hepatocyte injury in patients who receive extended donor&#xD;
      criteria(EDC)liver grafts based on changes in proteomic and metabolomic markers following&#xD;
      revascularization of the donor graft.&#xD;
&#xD;
      In reviewing the literature, no uniform extended criteria donor classification exists. The&#xD;
      characteristics most associated with liver graft failure appear to be cold ischemia time&#xD;
      greater than 10 hours, warm ischemia time greater than 40 minutes, donor age &gt; 55 years of&#xD;
      age, donor hospitalization &gt; 5 days, a donation after cardiac death (DCD) graft, and a split&#xD;
      graft. The researchers will exclude warm ischemia time as this is impossible to predict prior&#xD;
      to the transplantation. Any donor meeting at least one of the other criteria will be&#xD;
      classified as an EDC donor.&#xD;
&#xD;
      Hypothesis 1: Inhaled nitric oxide will improve overall outcome of liver recipients after EDC&#xD;
      liver transplantation&#xD;
&#xD;
        -  Suppression of oxidative injury will improve graft function postoperatively as measured&#xD;
           by International Normalized Ratio (INR) bilirubin, transaminases, and duration of&#xD;
           hospital stay.&#xD;
&#xD;
      Hypothesis 2: The mechanisms of therapeutic efficacy of inhaled nitric oxide is based on&#xD;
      reduction in post-reperfusion oxidative injury as readily measured by the detectable changes&#xD;
      in the protein and metabolic profiles in plasma of patients treated with inhaled-NO&#xD;
&#xD;
        -  Nuclear Magnetic Resonance (NMR)-based metabolic markers (xanthine end-products,&#xD;
           lactate, and hepatic osmolytes) that are consistent with acute liver injury will be&#xD;
           decreased in NO-treated recipients.&#xD;
&#xD;
        -  Protein markers of reperfusion injury (argininosuccinate synthase (ASS) and estrogen&#xD;
           sulfotransferase (EST-1) will be greater in the plasma of patients who are not treated&#xD;
           with inhaled-NO&#xD;
&#xD;
        -  Reduced oxidative injury will be reflected by a decrease in the number of mitochondrial&#xD;
           peroxiredoxins isoforms and the number that are oxidized in NO-treated liver recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated when the P.I. left the university.&#xD;
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine if Inhaled Nitric Oxide Has Beneficial Effects on Overall Outcome After Extended Criteria Donor (EDC) Liver Transplantation</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Construct a Plasma Metabolic/Protein Profile of I/R Injury in Transplanted Livers</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Examine the Effects of Nitric Oxide on Protein Synthesis and Metabolism Following Extended Criteria Donor Liver Transplantation</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Ischemia/Reperfusion Injury</condition>
  <condition>Oxidative Injury</condition>
  <arm_group>
    <arm_group_label>No nitric oxide</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitric Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive Nitric oxide and other standard inhaled anesthetics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery</description>
    <arm_group_label>Nitric Oxide</arm_group_label>
    <other_name>INOmax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 69 years of age&#xD;
&#xD;
          -  moderate to severe liver disease (MELD score 22 to 30)&#xD;
&#xD;
          -  is receiving a extended donor criteria liver graft&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  undergoing multi-organ transplant&#xD;
&#xD;
          -  70 years or older&#xD;
&#xD;
          -  diagnosed with hepatocarcinoma&#xD;
&#xD;
          -  diagnosed with either hepatopulmonary syndrome or pulmonary hypertension&#xD;
&#xD;
          -  pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J. Fiegel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <results_first_submitted>January 22, 2021</results_first_submitted>
  <results_first_submitted_qc>May 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extended Donor Criteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>No Nitric Oxide</title>
          <description>This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics</description>
        </group>
        <group group_id="P2">
          <title>Nitric Oxide</title>
          <description>Will receive Nitric oxide and other standard inhaled anesthetics&#xD;
Nitric Oxide: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Blood drawn using incorrect test tube; sample invalid</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics data was not collected one participant whose sample was invalid.</population>
      <group_list>
        <group group_id="B1">
          <title>No Nitric Oxide</title>
          <description>This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics</description>
        </group>
        <group group_id="B2">
          <title>Nitric Oxide</title>
          <description>Will receive Nitric oxide and other standard inhaled anesthetics&#xD;
Nitric Oxide: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cirrhosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Sclerosing Cholangitis (PSC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatty Liver (NASH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic Disease (METDIS) - Alpha-1-Antitrypsin Deficiency (A-1-A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone mets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Model for End-Stage Liver Disease Score</title>
          <description>The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.42"/>
                    <measurement group_id="B2" value="27.14" spread="3.64"/>
                    <measurement group_id="B3" value="26.75" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.59" spread="5.01"/>
                    <measurement group_id="B2" value="27.1" spread="5.83"/>
                    <measurement group_id="B3" value="26.89" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine if Inhaled Nitric Oxide Has Beneficial Effects on Overall Outcome After Extended Criteria Donor (EDC) Liver Transplantation</title>
        <time_frame>3 years</time_frame>
        <population>The outcome measure data are unavailable. This study was terminated when the P.I. left the university. Research Administration and the study team have made numerous unsuccessful attempts to obtain the outcome measure data.</population>
        <group_list>
          <group group_id="O1">
            <title>No Nitric Oxide</title>
            <description>This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Will receive Nitric oxide and other standard inhaled anesthetics&#xD;
Nitric Oxide: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine if Inhaled Nitric Oxide Has Beneficial Effects on Overall Outcome After Extended Criteria Donor (EDC) Liver Transplantation</title>
          <population>The outcome measure data are unavailable. This study was terminated when the P.I. left the university. Research Administration and the study team have made numerous unsuccessful attempts to obtain the outcome measure data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Construct a Plasma Metabolic/Protein Profile of I/R Injury in Transplanted Livers</title>
        <time_frame>3 years</time_frame>
        <population>The outcome measure data are unavailable. This study was terminated when the P.I. left the university. Research Administration and the study team have made numerous unsuccessful attempts to obtain the outcome measure data.</population>
        <group_list>
          <group group_id="O1">
            <title>No Nitric Oxide</title>
            <description>This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Will receive Nitric oxide and other standard inhaled anesthetics&#xD;
Nitric Oxide: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>To Construct a Plasma Metabolic/Protein Profile of I/R Injury in Transplanted Livers</title>
          <population>The outcome measure data are unavailable. This study was terminated when the P.I. left the university. Research Administration and the study team have made numerous unsuccessful attempts to obtain the outcome measure data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Examine the Effects of Nitric Oxide on Protein Synthesis and Metabolism Following Extended Criteria Donor Liver Transplantation</title>
        <time_frame>3 years</time_frame>
        <population>The outcome measure data are unavailable. This study was terminated when the P.I. left the university. Research Administration and the study team have made numerous unsuccessful attempts to obtain the outcome measure data.</population>
        <group_list>
          <group group_id="O1">
            <title>No Nitric Oxide</title>
            <description>This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Will receive Nitric oxide and other standard inhaled anesthetics&#xD;
Nitric Oxide: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>To Examine the Effects of Nitric Oxide on Protein Synthesis and Metabolism Following Extended Criteria Donor Liver Transplantation</title>
          <population>The outcome measure data are unavailable. This study was terminated when the P.I. left the university. Research Administration and the study team have made numerous unsuccessful attempts to obtain the outcome measure data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>No Nitric Oxide</title>
          <description>This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics</description>
        </group>
        <group group_id="E2">
          <title>Nitric Oxide</title>
          <description>Will receive Nitric oxide and other standard inhaled anesthetics&#xD;
Nitric Oxide: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nick Naughton</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-0833</phone>
      <email>nick.naughton@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

